Literature DB >> 25737147

Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents.

Eduardo Asín-Prieto1, Alicia Rodríguez-Gascón1, Arantxazu Isla2.   

Abstract

The alarming increase of resistance against multiple currently available antibiotics is leading to a rapid lose of treatment options against infectious diseases. Since the antibiotic resistance is partially due to a misuse or abuse of the antibiotics, this situation can be reverted when improving their use. One strategy is the optimization of the antimicrobial dosing regimens. In fact, inappropriate drug choice and suboptimal dosing are two major factors that should be considered because they lead to the emergence of drug resistance and consequently, poorer clinical outcomes. Pharmacokinetic/pharmacodynamic (PK/PD) analysis in combination with Monte Carlo simulation allows to optimize dosing regimens of the antibiotic agents in order to conserve their therapeutic value. Therefore, the aim of this review is to explain the basis of the PK/PD analysis and associated techniques, and provide a brief revision of the applications of PK/PD analysis from a therapeutic point-of-view. The establishment and reevaluation of clinical breakpoints is the sticking point in antibiotic therapy as the clinical use of the antibiotics depends on them. Two methodologies are described to establish the PK/PD breakpoints, which are a big part of the clinical breakpoint setting machine. Furthermore, the main subpopulations of patients with altered characteristics that can condition the PK/PD behavior (such as critically ill, elderly, pediatric or obese patients) and therefore, the outcome of the antibiotic therapy, are reviewed. Finally, some recommendations are provided from a PK/PD point of view to enhance the efficacy of prophylaxis protocols used in surgery.
Copyright © 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breakpoints; Monte Carlo simulation; PK/PD analysis; Pharmacodynamics; Pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 25737147     DOI: 10.1016/j.jiac.2015.02.001

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  52 in total

Review 1.  Antibiotic resistome of Salmonella typhi: molecular determinants for the emergence of drug resistance.

Authors:  Awanish Kumar; Anil Kumar
Journal:  Front Med       Date:  2021-06-04       Impact factor: 4.592

2.  Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections.

Authors:  Laura McEntee; Adam Johnson; Nicola Farrington; Jennifer Unsworth; Aaron Dane; Akash Jain; Nicole Cotroneo; Ian Critchley; David Melnick; Thomas Parr; Paul G Ambrose; Shampa Das; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.

Authors:  A Isla; A Canut; J Arribas; E Asín-Prieto; A Rodríguez-Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-19       Impact factor: 3.267

4.  Augmented Renal Clearance in Critically Ill Patients: A Systematic Review.

Authors:  Idoia Bilbao-Meseguer; Alicia Rodríguez-Gascón; Helena Barrasa; Arantxazu Isla; María Ángeles Solinís
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

5.  Semimechanistic Modeling of Eravacycline Pharmacodynamics Using In Vitro Time-Kill Data with MIC Incorporated in an Adaptive Resistance Function.

Authors:  Ken Nguyen; Timothy J Bensman; Xiaohui Tracey Wei; Jason N Moore
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  On the analysis of complex biological supply chains: From Process Systems Engineering to Quantitative Systems Pharmacology.

Authors:  Rohit T Rao; Megerle L Scherholz; Clara Hartmanshenn; Seul-A Bae; Ioannis P Androulakis
Journal:  Comput Chem Eng       Date:  2017-06-03       Impact factor: 3.845

Review 7.  Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.

Authors:  Jianguo Li; Mark Lovern; Todd Riccobene; Timothy J Carrothers; Paul Newell; Shampa Das; Angela K Talley; Margaret Tawadrous
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

8.  Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?

Authors:  Laura Herrera-Hidalgo; Arístides de Alarcón; Luis Eduardo López-Cortes; Rafael Luque-Márquez; Luis Fernando López-Cortes; Alicia Gutiérrez-Valencia; María Victoria Gil-Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

9.  Ampicillin and Ceftriaxone Solution Stability at Different Temperatures in Outpatient Parenteral Antimicrobial Therapy.

Authors:  L Herrera-Hidalgo; L E López-Cortes; R Luque-Márquez; J Gálvez-Acebal; A de Alarcón; L F López-Cortes; A Gutiérrez-Valencia; M V Gil-Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

10.  Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis.

Authors:  Antonin Praet; Laurent Bourguignon; Florence Vetele; Valentine Breant; Charlotte Genestet; Oana Dumitrescu; Anne Doleans-Jordheim; Philippe Reix; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.